HeartBeam Appoints CEO Robert Eno to Board to Support Commercialization and Growth.
ByAinvest
Monday, May 5, 2025 7:03 am ET1min read
BEAT--
Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. His appointment to the Board of Directors reflects the company's commitment to leadership and innovation in remote cardiac monitoring. The Board expanded from eight to nine members to accommodate this addition.
HeartBeam's 3D ECG technology, which captures the heart's electrical signals in 3 non-coplanar directions and synthesizes these signals into a 12-lead ECG, received FDA clearance for arrhythmia assessment in December 2024. The company plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software, which it submitted in January 2025. Eno's leadership has been instrumental in preparing HeartBeam for this milestone.
Rich Ferrari, Executive Chairman of the Board of Directors, commented, "Rob’s deep expertise in sales and go-to-market strategies perfectly complements the diverse skillset and experience of the Board and strengthens our strategic oversight as we move toward commercialization and long-term growth. We are confident that Rob’s perspective will be instrumental in helping HeartBeam achieve its vision of delivering powerful cardiac insights wherever the patient is."
Eno holds an MBA from the Stanford Graduate School of Business and a BA, with Honors and Distinction, from Stanford University. Prior to joining HeartBeam, he served as CEO of Preview Medical and held senior marketing and sales leadership roles at several other companies.
The appointment of Eno to the Board of Directors underscores HeartBeam's commitment to leveraging diverse expertise to drive commercial success and accelerate its mission to transform cardiac health management.
References:
[1] https://www.stocktitan.net/news/BEAT/heart-beam-appoints-ceo-robert-eno-to-board-of-directors-to-support-s1tr92o1uega.html
[2] https://www.stocktitan.net/news/AGRO/adecoagro-announces-changes-in-board-d1io9jd970aq.html
HeartBeam has appointed CEO Robert Eno to its Board of Directors to support US commercialization and growth. Eno, with over 30 years of experience in medical technology, has a proven track record of developing markets and launching disruptive technologies. He will leverage his expertise to drive commercial success and accelerate the Company's mission to transform cardiac health management.
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has appointed Robert Eno to its Board of Directors. Eno, who has over 30 years of experience in the medical technology industry, will bring his expertise in developing markets and launching disruptive technologies to support the company's US commercialization and growth efforts.Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. His appointment to the Board of Directors reflects the company's commitment to leadership and innovation in remote cardiac monitoring. The Board expanded from eight to nine members to accommodate this addition.
HeartBeam's 3D ECG technology, which captures the heart's electrical signals in 3 non-coplanar directions and synthesizes these signals into a 12-lead ECG, received FDA clearance for arrhythmia assessment in December 2024. The company plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software, which it submitted in January 2025. Eno's leadership has been instrumental in preparing HeartBeam for this milestone.
Rich Ferrari, Executive Chairman of the Board of Directors, commented, "Rob’s deep expertise in sales and go-to-market strategies perfectly complements the diverse skillset and experience of the Board and strengthens our strategic oversight as we move toward commercialization and long-term growth. We are confident that Rob’s perspective will be instrumental in helping HeartBeam achieve its vision of delivering powerful cardiac insights wherever the patient is."
Eno holds an MBA from the Stanford Graduate School of Business and a BA, with Honors and Distinction, from Stanford University. Prior to joining HeartBeam, he served as CEO of Preview Medical and held senior marketing and sales leadership roles at several other companies.
The appointment of Eno to the Board of Directors underscores HeartBeam's commitment to leveraging diverse expertise to drive commercial success and accelerate its mission to transform cardiac health management.
References:
[1] https://www.stocktitan.net/news/BEAT/heart-beam-appoints-ceo-robert-eno-to-board-of-directors-to-support-s1tr92o1uega.html
[2] https://www.stocktitan.net/news/AGRO/adecoagro-announces-changes-in-board-d1io9jd970aq.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet